Merck & Co., Inc. Equity Method Investment, Realized Gain (Loss) on Disposal
Merck & Co., Inc. (MRK) reported Equity Method Investment, Realized Gain (Loss) on Disposal of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-28.
Discontinued › Income Statement › Other Income
us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal · last filed 2017-02-28
- Merck & Co., Inc. equity method investment, realized gain (loss) on disposal for the quarter ending 2015-12-31 was $0.00.
- Merck & Co., Inc. equity method investment, realized gain (loss) on disposal for the quarter ending 2015-09-30 was $0.00.
- Merck & Co., Inc. equity method investment, realized gain (loss) on disposal for the quarter ending 2014-12-31 was $0.00.
- Merck & Co., Inc. equity method investment, realized gain (loss) on disposal for the quarter ending 2014-09-30 was $0.00.
- Merck & Co., Inc. equity method investment, realized gain (loss) on disposal for fiscal 2016 was $0.00.
- Merck & Co., Inc. equity method investment, realized gain (loss) on disposal for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- Merck & Co., Inc. equity method investment, realized gain (loss) on disposal for fiscal 2014 was $741.00M.
- Merck & Co., Inc. equity method investment, realized gain (loss) on disposal for fiscal 2013 was $0.00.
| Period end | Equity Method Investment, Realized Gain (Loss) on Disposal 3 month | Equity Method Investment, Realized Gain (Loss) on Disposal 6 month | Equity Method Investment, Realized Gain (Loss) on Disposal 9 month | Equity Method Investment, Realized Gain (Loss) on Disposal 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-02-28 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $0.00 derived: sum of 2 quarters · filed 2017-02-28 | $0.00 10-K · filed 2017-02-28 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $0.00 10-Q · filed 2015-11-05 | ||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-06 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $0.00 derived: sum of 2 quarters · filed 2017-02-28 | $741.00M derived: sum of 3 quarters · filed 2017-02-28 | $741.00M 10-K · filed 2017-02-28 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $741.00M derived: sum of 2 quarters · filed 2015-11-05 | $741.00M 10-Q · filed 2015-11-05 | |
| 2014-06-30 | $741.00M 10-Q · filed 2015-08-06 | $741.00M 10-Q · filed 2015-08-06 | ||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $0.00 derived: sum of 2 quarters · filed 2016-02-26 | $0.00 10-K · filed 2016-02-26 | |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $0.00 10-Q · filed 2014-11-10 | ||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-07 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-02-27 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $136.00M derived: sum of 2 quarters · filed 2014-02-27 | $136.00M 10-K · filed 2014-02-27 | |
| 2011-09-30 | $136.00M 10-Q · filed 2012-11-09 | $136.00M 10-Q · filed 2012-11-09 | ||
| 2009-12-31 | $3.16B 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |